Arch Cardiovasc Dis 2022 Apr 20;115(4):235-242. Epub 2022 Apr 20.
Centres for Heart Valve Innovation and for Cardiovascular Innovation, St. Paul's and Vancouver General Hospital, Vancouver BC V6E 1M7, Canada; Division of Cardiology, University of British Columbia & St. Paul's Hospital, Vancouver, BC V6E 1M7, Canada; Cardiovascular Translational Laboratory, Centre for Heart Lung Innovation, University of British Columbia & St. Paul's Hospital, Vancouver, BC V6E 1M7, Canada. Electronic address:
Since the first-in-human procedure in 2002, transcatheter aortic valve implantation (TAVI) has become a well-established therapeutic option for severe aortic stenosis, and is offered increasingly to patients at lower surgical risk, who are typically younger. Increasing lifespan carries concerns that "minor" complications that may have little impact in elderly patients could have a greater long-term impact in younger patients. Issues such as mild paravalvular regurgitation, hypoattenuated leaflet thickening, atrioventricular block with need for permanent pacemaker implantation or future coronary access may have a substantial cumulative undesirable impact. Read More